Currently, at the peak of the disclosure of performance forecasts, according to the Stock Times and Databao statistics, as of the close of trading on July 15, based on the currently disclosed performance reports and lower forecast net profit limits, there are 20 innovative drug concept stocks with a year-on-year increase in net profit in the first half of 2026. The highest profit is expected to be in Aodong, Jilin. The company expects net profit of 1,922 billion yuan to 2,179 billion yuan for the first half of 2026, an increase of 50% to 70% year on year. The main reason for the sharp increase in performance is the company's investment income. Also expected to be profitable are Tianshili, HiCisco, Huahai Pharmaceutical, Kanglong Chemical, and Zhaoyan New Pharmaceutical.

Currently, at the peak of the disclosure of performance forecasts, according to the Stock Times and Databao statistics, as of the close of trading on July 15, based on the currently disclosed performance reports and lower forecast net profit limits, there are 20 innovative drug concept stocks with a year-on-year increase in net profit in the first half of 2026. The highest profit is expected to be in Aodong, Jilin. The company expects net profit of 1,922 billion yuan to 2,179 billion yuan for the first half of 2026, an increase of 50% to 70% year on year. The main reason for the sharp increase in performance is the company's investment income. Also expected to be profitable are Tianshili, HiCisco, Huahai Pharmaceutical, Kanglong Chemical, and Zhaoyan New Pharmaceutical.